This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wit, J. M. Articles by Rekers-Mombarg, L. T. M. Search for Related Content PubMed PubMed Citation Articles by Wit, J. M. Articles by Rekers-Mombarg, L. T. M.

Final Height Gain by GH Therapy in Children with Idiopathic Short Stature Is Dose Dependent

Department of Pediatrics (J.M.W., L.T.M.R-.M.), Leiden University Medical Center, Leiden, The Netherlands; and Department of Educational Administration and Management (L.T.M.R.-M.), Faculty of Educational Science and Technology, University of Twente, Enschede, The Netherlands

Address all correspondence and requests for reprints to: Dr. J. M. Wit, Department of Pediatrics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. E-mail: JMWit{at}lumc.nl

Abstract

Recombinant human GH therapy to children with idiopathic short stature (ISS) increases growth velocity, but its effect on final height (FH) is still uncertain. The aim of this study was to investigate the effect of recombinant human GH on FH of patients with ISS who were treated according to two protocols in comparison to untreated historical controls. In study 1 (n = 24), all patients were treated with 14 IU (4.6 mg)/m² body surface·wk in the first year; thereafter the dosage was doubled if the growth response was insufficient. In study 2 (n = 34), patients were randomized into three arms: 18 IU (6 mg)/m²·wk; 27 IU (9 mg)/m²·wk; and 18 IU/m²·wk in the first year, followed by 27 IU/m²·wk thereafter. Observed or estimated FH was available for 53 patients. Thirty-four untreated controls from the same centers were available for comparison. Mean FH SD score in GH-treated children was -2.1, vs. -2.4 in controls (-2.4) (NS), but height SD score gain (1.3 vs. 0.7) and the difference between FH and predicted adult height (4.0 vs. 0.8 cm) were significantly greater. The growth response on an initial dosage of 27 IU/m²·wk (6.9 cm) was significantly better than on other regimens (2.8 cm). We conclude that a GH dosage of 27 IU (9 mg)/m²·wk to prepubertal children with ISS leads to a mean FH gain of approximately 7 cm, whereas regimens starting on lower dosages are less efficacious.

This article has been cited by other articles:

				M. O Savage, C. Camacho-Hubner, A. David, L. A Metherell, V. Hwa, R. G Rosenfeld, and A. J L Clark Idiopathic short stature: will genetics influence the choice between GH and IGF-I therapy? Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S33 - S37. [Abstract] [Full Text] [PDF]

				S. A. van Gool, G. A. Kamp, H. Visser-van Balen, D. Mul, J. J. J. Waelkens, M. Jansen, L. Verhoeven-Wind, H. A. Delemarre-van de Waal, S. M. P. F. de Muinck Keizer-Schrama, G. Leusink, et al. Final Height Outcome after Three Years of Growth Hormone and Gonadotropin-Releasing Hormone Agonist Treatment in Short Adolescents with Relatively Early Puberty J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1402 - 1408. [Abstract] [Full Text] [PDF]

				B. J. Crowe, L. T. M. Rekers-Mombarg, K. Robling, A. M. Wolka, G. B. Cutler Jr., J. M., and Wit for the European Idiopathic Short Stature Grou Effect of Growth Hormone Dose on Bone Maturation and Puberty in Children with Idiopathic Short Stature J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 169 - 175. [Abstract] [Full Text] [PDF]

				M. T. Stein, S. D. Frasier, and B. Stabler Parent Requests Growth Hormone for Child With Idiopathic Short Stature Pediatrics, November 1, 2004; 114(5/S2): 1478 - 1482. [Full Text] [PDF]

				E. W. Leschek, S. R. Rose, J. A. Yanovski, J. F. Troendle, C. A. Quigley, J. J. Chipman, B. J. Crowe, J. L. Ross, F. G. Cassorla, W. F. Blum, et al. Effect of Growth Hormone Treatment on Adult Height in Peripubertal Children with Idiopathic Short Stature: A Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3140 - 3148. [Abstract] [Full Text] [PDF]

				J.-C. Carel, P. Chatelain, P. Rochiccioli, and J.-L. Chaussain Improvement in Adult Height after Growth Hormone Treatment in Adolescents with Short Stature Born Small for Gestational Age: Results of a Randomized Controlled Study J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1587 - 1593. [Abstract] [Full Text] [PDF]